GHK-Cu published research history: - First isolated and characterized: 1973 - Continuous peer-reviewed publication: 50+ years - Published research covering: wound healing, skin biology, COPD, oxidative stress, bone, skeletal muscle, gastrointestinal, neurological, gene expression, aging - Mechanistic characterization: Multiple pathways identified, SIRT1 direct binding confirmed in 2025 - Cell and animal model validation: Extensive across multiple tissue types and species Matrixyl 3000 (palmitoyl tripeptide-1 + palmitoyl tetrapeptide-7) research: - Commercial introduction: Early 2000s - Research base: Primarily cosmetic science and dermatology literature - Mechanistic characterization: Primarily focused on TGF-beta receptor and IL-6 pathways - Depth: Narrower tissue focus, smaller body of published mechanistic research For researchers who need a compound with extensive published mechanistic context, detailed gene expression data, or research across multiple tissue types, GHK-Cu's research depth is substantially greater
This delayed gastric emptying contributes to appetite suppression and blood sugar control, which is why these drugs work for weight loss and diabetes management
Shi LZ, Fu T, Guan B, Chen J, Blando JM, Allison JP, et al
Tirzepatide's prescribing information carries specific birth-control guidance around starting the medication and each dose increase
